Amneal Pharmaceuticals, Inc. Form 10-K for fiscal year 2021 (Emverm in the Specialty portfolio) (2022)

Government Record · Amneal Pharmaceuticals, Inc. (filed with the U.S. Securities and Exchange Commission) · March 1, 2022

Amneal's annual report lists Emverm (mebendazole) 100 mg chewable tablets as one of its promoted specialty products.

our promoted Specialty portfolio also includes Unithroid (levothyroxine sodium), for the treatment of hypothyroidism, which is sold under a license and distribution agreement with Jerome Stevens Pharmaceuticals, Inc., and Emverm (mebendazole) 100 mg chewable tablets, for the treatment of pinworm, whipworm, common roundworm, common hookworm and American hookworm in single or mixed infections.

Amneal's annual report lists Emverm (mebendazole) 100 mg chewable tablets as one of its promoted specialty products. SEC filing (company document, LINK). Amneal's own description of the product's indications (pinworm, whipworm, roundworm, common hookworm, American hookworm). Emverm is an ANDA product (ANDA 073580, MBA-10), not a Janssen NDA, and Amneal distributes it (MBA-12) with Alcami as contract manufacturer. No dose data in the quoted passage.